The review, led by Vivian Ibienebakabobo Promise of Bayelsa Medical University in Nigeria together with Ebinyo Rebecca Aseibai and Sylvester Chibueze Izah, is a scoping review: a systematic map of all the primary human evidence published between 1999 and 2025 linking vaccines to antibiotic use or microbiological resistance. Following Joanna Briggs Institute guidance and reported under the PRISMA-ScR framework, the team searched PubMed in June 2026, supplemented by Europe PMC, the WHO Global Index Medicus, Google Scholar and citation chaining. The initial search returned 7,433 records. After rigorous screening — with one reviewer conducting initial assessment and a second author independently verifying every inclusion — 74 primary studies made the final cut: 35 examining antibiotic use and 39 examining direct resistance outcomes.

The logic behind the vaccine-resistance connection is elegant. Antibiotic resistance is fundamentally a problem of selection pressure: the more antibiotics circulate in a population, the more opportunities bacteria have to evolve defenses. Vaccines attack that pressure at its source. By preventing infections in the first place, they eliminate the illnesses that trigger antibiotic prescriptions. By blocking transmission of vaccine-targeted strains, they reduce the pool of bacteria that can acquire or spread resistance genes. And by shrinking the total burden of disease, they lower the sheer volume of antibiotics dispensed across entire communities — including to people who were never vaccinated at all, through herd protection.

The influenza findings are the review’s most immediately actionable. Across multiple studies, flu vaccination generally reduced antibiotic exposure for respiratory infections — the category where inappropriate prescribing is most rampant, since clinicians and patients alike struggle to distinguish viral illness from bacterial. The effect was not universal: some trials returned null results, and seasonal variability in how well the vaccine matched circulating strains muddied the picture from year to year. But the overall signal was consistent enough for the authors to flag influenza vaccination as carrying the strongest evidence base for reduced prescribing. One striking quantitative example: an estimated 8 percent vaccine effectiveness against outpatient antimicrobial purchases, meaning the shot didn’t just prevent illness — it kept people out of pharmacies with prescriptions in hand.

Pneumococcal conjugate vaccines, which protect against Streptococcus pneumoniae, delivered perhaps the review’s most dramatic numbers. Introduced into childhood immunization schedules worldwide over the past two decades, these vaccines produced modest reductions in all-cause antibiotic use but much larger reductions when measured against specific syndromes. The indirect effects were substantial too: one study documented a 14.7 percent drop in otitis-related antimicrobial purchases — ear infections being a classic driver of pediatric antibiotic prescriptions. Most remarkable of all was the long-term United States surveillance data on resistant disease. Among children under five, nonsusceptible invasive pneumococcal disease fell from 43.9 cases per 100,000 to just 3.2 per 100,000 following vaccine introduction. That is not a marginal improvement. That is the near-erasure of an entire category of drug-resistant childhood infection.

The evidence extends well beyond the two usual suspects. An investigational maternal respiratory syncytial virus vaccine — given to pregnant women to protect their newborns — reduced infant antimicrobial prescribing by 12.9 percent, a finding with enormous implications as RSV immunization rolls out globally. Studies of rotavirus, COVID-19 and typhoid conjugate vaccines rounded out the picture, demonstrating that the vaccination-to-antibiotic pathway operates across respiratory, gastrointestinal and enteric disease alike. Each vaccine that prevents a common infection removes a predictable slice of antibiotic demand from the system, and the review makes clear that this mechanism is general, not an artifact of any single pathogen or product.

The authors are careful, however, not to oversell. Two significant limitations temper the conclusions. The first is serotype replacement: when a vaccine eliminates the pneumococcal strains it targets, other strains sometimes fill the ecological vacuum, and those replacements can themselves carry resistance. The second is ecological confounding — the difficulty of attributing population-level changes in resistance to vaccination alone when prescribing habits, diagnostic practices and infection control measures shift simultaneously. For total antimicrobial resistance burden, the review concludes, inference remains limited. The strongest claims are reserved for what the data actually support: reduced influenza-associated prescribing and dramatic declines in resistant vaccine-type pneumococcal disease.

Methodologically, the review is a model of transparency for its genre. The team prespecified a term-based prioritization step before detailed title, abstract and full-record assessment, charted data by vaccine type, population, study design, outcome and effect estimate, and used design-appropriate Joanna Briggs Institute quality domains to inform interpretation rather than to exclude studies outright. That inclusiveness is the point of a scoping review: rather than pooling effect sizes into a single meta-analytic estimate, it maps the terrain, revealing where the evidence is dense, where it is thin, and where the field should dig next. What emerges is a terrain with deep wells of evidence around influenza and pneumococcus, and promising but sparser coverage elsewhere.

The strategic implications are considerable. Antimicrobial resistance is projected to claim millions of lives annually in the coming decades, and the pipeline for genuinely novel antibiotics remains tragically thin. Stewardship programmes — which try to change prescribing behavior through guidelines, diagnostics and auditing — have shown only modest and uneven success. Vaccination offers something stewardship cannot: it reduces the demand for antibiotics structurally, before any prescription decision is ever made. In the authors’ framing, vaccine programmes should be treated as an upstream component of antimicrobial stewardship, working in concert with diagnostic stewardship and prescribing interventions rather than as a separate public health silo.

That integration, the review argues, requires sustained infrastructure: ongoing surveillance of pneumococcal serotypes, genomic monitoring of resistant strains, and continuous tracking of antimicrobial consumption at the population level. Without that monitoring, the gains documented here — the collapsing rates of resistant childhood pneumonia, the thousands of prescriptions never written after a flu shot — cannot be verified, maintained or extended to new vaccines as they arrive. The message for policymakers is deceptively simple: every dollar spent on immunization is quietly a dollar spent on preserving antibiotic effectiveness. The message for everyone else is simpler still. The next time you roll up your sleeve for a vaccine you consider routine, you are not just protecting yourself from a virus. You are helping to keep the antibiotics working — for the person beside you, and for everyone who will need them after.

Subject of Research: The effects of vaccination programmes on antibiotic consumption and antimicrobial resistance

Article Title: Effects of vaccination programmes on antibiotic consumption and antimicrobial resistance: a global scoping review

Article References: Promise, V. I., Aseibai, E. R., & Izah, S. C. (2026). Effects of vaccination programmes on antibiotic consumption and antimicrobial resistance: a global scoping review. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14691-8

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14691-8

Keywords: vaccination, antimicrobial resistance, antibiotic consumption, influenza vaccine, pneumococcal conjugate vaccine, antimicrobial stewardship, scoping review, public health, infectious diseases, RSV vaccine, serotype replacement, antibiotic prescribing